Liver Cancer

Case Summary:

S.R. is a patient with bile duct cancer who came to us through daughter, looking for a treatment alternative that could help her fight the disease.

When we reviewed the case documentation, we were able to confirm that it was an intrahepatic cholangiocarcinoma, with metastasis to the liver and regional and intraperitoneal lymph nodes.

Surgery had been performed, but it was not possible to remove the tumor due to its large size. Palliative chemotherapy treatment was pending.

Once the case had been analyzed by our specialists, we informed the family what they could expect with Escozul™ and the possibilities of achieving good results. Cholangicarcinoma is generally a type of cancer with aggressive behavior and poor prognosis, which does not usually respond very well to the conventional treatment options available and often generates numerous complications that end up being fatal for the patient.

Each dose of Escozul™ is personalized, specific to the type of tumor and its aggressiveness. These doses can change over time according to the results observed in the patient. This requires an effective communication between the patient and our medical team to allow us to make the appropriate recommendations on different aspects. If the patient or family members do not maintain fluid communication with us, then the results with Escozul™ will not be as expected.

S.R. started treatment with Escozul™ in October 2017. He subsequently started palliative chemotherapy and other natural treatments such as zeolite and amalaki.

Evolution, Follow-up and Current Results:

Chest, abdomen and pelvis CT scan performed 3 months after treatment, in January 2018, shows decrease in size of the initial liver lesion from 97x74mm to 90 mm and no mention of the presence of regional and retroperitoneal adenopathies that were described in the initial CT scan in August 2017.

Despite the short time of treatment, this is a very important result as it is not the response usually seen in patients with this type of cancer, in which the tendency is that the disease does not stop its progression.

S.R. continues to be treated with Escozul™ with progressive dose increases, with the aim of maintaining and improving the results obtained so far.

As we always say, it is important to point out that it is not possible to generalize any result with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only working together and constant communication allow to keep the doses of Escozul™ personalized and functional against tumors.

It is also important to say that all the medical information of the case is available for consultation, as well as the contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated under the Escozul™ Protocol, you should know the following: Escozul™ is a product that we are still investigating, including its other properties such as analgesic and anti-inflammatory, therefore it is not a commercial product, i.e. it cannot be sold. Each case that wishes to enter our protocol must be evaluated and approved because Escozul™ is not effective in all types of tumors. Once approved, the patient and his family members must commit to maintain a fluid contact with our medical team.

To enter the protocol you must send us an email to: servicios@lifescozulcuba.com indicating the patient's age, the type of cancer and the patient's physical and emotional state. This is the first step, and a specialist will take charge of the case. Our response time is an hour or two because each case is answered personally, not automatically. The idea is that the communication we establish is always governed by a professional and humane treatment.

Prepared by LifEscozul™ Group May/2018

Medical Documents

E.B. is a 56-year-old female patient who came to us in June 2017, with a recent diagnosis of stage IV intrahepatic cholangiocarcinoma that had failed to be removed, with a very limited life prognosis. After 6 months of treatment we were able to stabilize the disease and begin to decrease the size of tumor lesions, in addition to having exceeded the prognosis for life and improved quality of life.

Case summary:

E.B. came to us in June 2017, through her brother and niece who, given the poor prospects of evolution and treatments given to the patient, decided to launch themselves into the search for some natural option that could represent a hope of life for E.B. She presented a liver cancer that could not be removed in surgery due to the presence of metastases. The oncologists in his country initially indicated that the application of chemo and radiotherapy in this case would not have a positive effect.

When we received the case documents we were able to confirm that E.B. presented a lesion on the left side of the liver compatible with intrahepatic cholangiocarcinoma in segments II and III and metastasis in the liver, in addition to regional lymph node involvement. He had an initial prognosis of 1 week to two months of life.

As for symptoms, he presented back and abdominal pain, which made it difficult to rest.

Once the case was analyzed by our specialists, we informed the family what they could expect with Escozul™ and the possibilities of achieving good results. In cases where the disease is advanced and treatment options are limited, there is not always the best chance of obtaining a positive result.

Each dose of Escozul™ is personalized, specific to the type and aggressiveness of the tumor. These doses can change over time according to the results observed in the patient. This requires an effective communication between the patient and our medical team to allow us to make the appropriate recommendations on different aspects. If the patient or family members do not maintain fluid communication with us, then the results with Escozul™ will not be as expected.

E.B. started treatment with Escozul™ in July 2017.

Evolution, Follow-up and Current Results:

By September 2017, we were informed by E.B.'s family members that they had remained well, with mild upper abdominal discomfort and that she was continuing with Escozul™ and on palliative treatment. At that time the patient could sleep normally and had a good appetite.

A CT scan performed in September showed growth of the primary lesion and the appearance of a new nodule, which implied that although the symptoms had improved, the disease had not yet been controlled, although this is not expected after only two months of treatment.

Faced with this situation and being a type of cancer that is difficult to treat and was showing rapid progression, we proceeded to perform a new dose increase.

By February 2018 we received a new update on the case of E.B. We were told that he was physically well although he had finally received a few cycles of palliative chemotherapy.

The CT scan performed at the end of January, 6 months after treatment, showed stability of the disease even with slight decrease in size of tumor lesions. The primary lesion decreased from 13.2×6.4cm to 12×5.5cm. There has also been a decrease in size of other hepatic and lymph node lesions and stability of the remaining metastases.

In this case we have managed to control the disease, and begin to reduce it, improve the quality of life, and far exceed the life expectancy that was originally expected for E.B.. We hope to continue to obtain good results in the future and to contribute to his being able to continue enjoying life with his loved ones.

 As we always say, it is important to point out that it is not possible to generalize any results with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only by working together and constant communication, it is possible to keep the doses of Escozul™ personalized and functional against tumors.

It is also important to say that all the medical information of the case is available for consultation, as well as contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated under the Escozul™ Protocol, you should know the following: Escozul™ is a product that we are still investigating, including its other properties such as analgesic and anti-inflammatory, therefore it is not a commercial product, i.e. it cannot be sold. Each case that wishes to enter our protocol must be evaluated and approved because Escozul™ is not effective in all types of tumors. Once approved, the patient and his family members must commit to maintain a fluid contact with our medical team.

To enter the protocol you must send us an email to: servicios@lifescozulcuba.com indicating the patient's age, the type of cancer and the patient's physical and emotional state. This is the first step, and a specialist will take charge of the case. Our response time is an hour or two because each case is answered personally, not automatically. The idea is that the communication we establish is always governed by a professional and humane treatment.

Prepared by LifEscozul™ Group February/2018

Medical Documents

Aida is a 66 year old patient, who came to us in July 2016 with a diagnosis of advanced liver tumor, with poor prospects of evolution, in this case the specialists in her country were talking about 2 to 12 months of survival. He has been on treatment with Escozul™ for 15 months already, he has managed in this time, to reduce the size of the disease by more than 70% and is stable and with good quality of life.

Summary of the case:

We share the case of a 65-year-old patient who came to us in July 2016, with a diagnosis of advanced liver tumor with multiple lymph node involvement.

When we received the medical documentation we were able to ascertain that Aida had a liver tumor in the left lobe of 10cm in greatest diameter, secondary tumor formations in liver, and involvement to periportal and portocaval lymph nodes up to 3.5cm, pericellular and retroperitoneal intercavo aortic and left para-aortic up to 1.5cm, mesenteric up to 1.8cm, and in epicardial adipose tissue up to 1.8cm. It had initially been thought to be a cholangiocarcinoma or intrahepatic bile duct tumor, later demonstrated by biopsy to be a poorly differentiated adenocarcinoma not compatible with cholangiocarcinoma. In March 2017, new biopsy suggested that it was a cirrhotic variant hepatocellular carcinoma.

In terms of symptoms, she presented pain in the liver area and considerable weight loss.

Once the case was analyzed by our specialists, we informed the family what they could expect with Escozul™ and the possibilities of achieving good results. In this case the probabilities were not the best, due to the evolution perspectives for this type of cancer.

Each dose of Escozul™ is personalized, specific to the type of tumor and its aggressiveness. These doses can change over time according to the results observed in the patient. This requires an effective communication between the patient and our medical team to allow us to make the appropriate recommendations on different aspects. If the patient or family members do not maintain fluid communication with us, then the results with Escozul™ will not be as expected.

Aida started treatment with Escozul™ in July 2016, without being undergoing any other treatment.

Evolution, Follow-up and Current Results:

Within two weeks of starting treatment Aida's appetite had improved noticeably, she had maintained her weight, she felt more energetic than before, and the pains were mild and only when she was sitting for a long time or if she walked a lot, her countenance had also improved.

By September 2016 Aida's mood was good, she had regained her appetite managing to gain 1 kg of weight, she was not yellow or drooping.

In mid-October 2016, 3 months after starting treatment with Escozul™, without having received any other treatment, a new CT scan showed that the tumor in liver had shrunk to 5.0cm (50% of its original size), all tumor nodules in liver had decreased in size also to less than 1cm. Nodal involvement in the various locations had also decreased in size.

By December 2016, further decrease in size of the main tumor with diameter greater than 2.6cm was observed.

In March 2017, a new examination showed a slight growth of the main tumor for a size of 3.0cm and a discrete increase in size of the lymph node lesions, it was then decided to apply a new dose change to combat this progression of the disease, which was further described as tumor of aggressive appearance.

The new examination performed in June 2017, showed that the tumor lesions were stable with respect to the previous study.

By July 2017, one year after starting Escozul™, she was started on palliative chemotherapy which she has tolerated well.

On examination in September 2017, the main liver lesion remained stable and decreased size of nodal involvement was observed.

In this case it has been achieved in a first year in which the patient only used Escozul™ to reduce the primary lesion by about 70% of its size, as well as to decrease the size of the lymph node involvement. At present, Aida's disease is stable and her life expectancy is better, in addition to having recovered her quality of life.

It is important to mention that Aida's family, specifically her daughter, has been in constant contact with our medical team. This means that we have had all the necessary elements to give the best possible follow-up to the case and take the appropriate measures to obtain the best possible results.

As we always say, it is important to point out that it is not possible to generalize any result with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only working together and constant communication allow to keep the doses of Escozul™ personalized and functional against tumors.

It is also important to say that all the medical information of the case is available for consultation, as well as the contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated under the Escozul™ Protocol, you should know the following: Escozul™ is a product that we are still investigating, including its other properties such as analgesic and anti-inflammatory, therefore it is not a commercial product, i.e. it cannot be sold. Each case that wishes to enter our protocol must be evaluated and approved because Escozul™ is not effective in all types of tumors. Once approved, the patient and his family members must commit to maintain a fluid contact with our medical team.

To enter the protocol you must send us an email to: servicios@lifescozulcuba.com indicating the patient's age, the type of cancer and the patient's physical and emotional state. This is the first step, and a specialist will take charge of the case. Our response time is an hour or two because each case is answered personally, not automatically. The idea is that the communication we establish is always governed by a professional and humane treatment.

Prepared by LifEscozul™ Group October/2017

Medical Documents

Laura is a 48 year old patient, who was diagnosed with bile duct cancer in 2011 and underwent surgery. In 2013 liver mass compatible with cholangiocarcinoma reappeared, despite the patient being on chemotherapy. She came to us in March 2017 looking for a treatment that could offer her better life expectancy, and chances to fight this difficult disease.

Case summary:

We share today the case of a 48-year-old patient who came to us in March 2017, with a diagnosis of bile duct cancer successfully operated in 2011, but with new onset of tumor in inoperable liver in 2013. In the first three months of treatment, we were able to start to decrease the size of the tumor.

When we received the medical documentation we were able to ascertain that Laura had bile duct cancer, compatible with nuclear grade III cholangiocarcinoma. She had been operated with hepatectomy in 2011 extracting the tumor, but from 2013 a liver tumor identified as cholangiocarcinoma, not operable, began to appear again in imaging tests, despite the fact that Laura was undergoing chemotherapy.

In terms of symptoms, she reported mild and occasional pain in the abdomen, tiredness, chronic fatigue, difficulty with food and rest, mostly related to the administration of chemotherapy.

Once the case was analyzed by our specialists, we informed the patient about what she could expect with Escozul™ and the possibilities of achieving good results.

Each dose of Escozul™ is personalized, specific to the type of tumor and its aggressiveness. These doses can change over time according to the results observed in the patient. This requires an effective communication between the patient and our medical team to allow us to make the appropriate recommendations on different aspects. If the patient or family members do not maintain fluid communication with us, then the results with Escozul™ will not be as expected.

Laura started treatment with Escozul™ in March 2017. She had been on chemotherapy since her first surgery.

Evolution, Follow-up and Current Results:

At the time of starting escozul the size of the tumor in the liver was 39mm in its major axis and had been that size since December 2016. At this time, three months after treatment, the tumor size decreased by 2mm, being now at 37mm its major axis. According to results the tumor is also better delimited.

At this moment Laura continues in treatment with Escozul™ with increasing doses, seeking to improve the results obtained and help her to have a better quality of life and better survival expectancy.

In this case it has been achieved, to begin to reduce the size of the tumor that had stabilized since December, despite continuing chemotherapy. Although the treatment time is still very short, this is an encouraging result; we hope that it will continue to improve in the coming months.

In new examination performed in September 2017, the disease has remained stable, with no growths. Due to the good results obtained in the previous scan, Laura has been resting from chemotherapy since June and has been on Escozul™ alone for the last three months.

In December 2017, 9 months into treatment, of which she has been the last 6 months on Escozul™ alone, it is noted in new scan that the tumor has shrunk a further 5mm, for a total of 7mm reduction since she started. Laura's physical condition continues to be excellent.

As we always say, it is important to point out that it is not possible to generalize any result with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only by working together and constant communication can the doses of Escozul™ be kept personalized and functional against tumors.

It is also important to say that all the medical information of the case is available for consultation, as well as contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated under the Escozul™ Protocol, you should know the following: Escozul™ is a product that we are still investigating, including its other properties such as analgesic and anti-inflammatory, therefore it is not a commercial product, i.e. it cannot be sold. Each case that wishes to enter our protocol must be evaluated and approved because Escozul™ is not effective in all types of tumors. Once approved, the patient and his family members must commit to maintain a fluid contact with our medical team.

To enter the protocol you must send us an email to: servicios@lifescozulcuba.com indicating the patient's age, the type of cancer and the patient's physical and emotional state. This is the first step, and a specialist will take charge of the case. Our response time is an hour or two because each case is answered personally, not automatically. The idea is that the communication we establish is always governed by a professional and humane treatment.

Prepared by LifEscozul™ Group May/2017

Medical Documents

Initial Diagnosis:

We received the medical documents and description of the physical conditions and our team proceeded to analyze the case. During the analysis it was corroborated that it was a moderately differentiated adenocarcinoma in liver tissue compatible with cholangiocarcinoma, with an approximate tumor size of 66×48 mm.

Patient's condition before starting treatment:

Regarding symptoms Angelina indicated that she felt discomfort in the liver area.

Treatment with Escozul™:

The patient's daughter was informed of the case analysis and perspectives with the use of Escozul™. A dosage was designed in order to obtain the best possible results in a short period of time, and it was prepared. Angelina was started on Escozul™ in April 2016.

Evolution, Follow-up and Current Results:

Two months after starting treatment, in new ultrasound performed, the tumor size had decreased to 49x47mm.

In a new ultrasound in August 2016, the tumor measured 14×9 mm, presenting a reduction of approximately 95% of its size at the beginning of the treatment. The patient is physically well, eats well, rests well and continues her life with the support and affection of her family.

In this case, the reduction in tumor size is very important, which certainly implies an increase in the patient's life expectancy with quality. We hope that having presented such a good response in the first months of treatment, we can continue to move forward with positive results.

Summary:

As we always say, it is important to point out that it is not possible to generalize any results with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only working together and constant communication allow us to keep the doses of Escozul™ personalized and functional against tumors.

It is also important to say that all the medical information of the case is available for consultation, as well as the contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

Medical Documents

Initial Diagnosis:

She was found to have a 20cm tumor in the liver, involving large vessels, with metastases in abdominal nodes and hepatic hilum, fluid accumulation in abdomen and abdominal pain. The cancer was determined to be inoperable due to the size of the tumor and its proximity to large blood vessels.

Treatments:

He started with chemotherapy in July 2013, as the only conventional treatment option, despite the fact that this type of cancer does not have a good response to chemotherapy, due to this he resorted to seek other treatment alternatives, starting with Escozul™ at the end of July 2013. It is worth remembering that Escozul™ is a harmless natural product obtained from the venom of the Blue Scorpion (endemic to Cuba), dissolved in water; which has proven to be able to kill tumor cells without affecting healthy cells.

Initial treatment results:

After the first two weeks of treatment she reports that although she continued on chemotherapy, she was tolerating it better, improved quality of rest and nutrition as well as the ability to perform physical exertion.

Evolution of the case:

In September 2013, tumor shrinkage from 20cm to 15cm, and disappearance of lymph node metastases, abdominal fluid accumulation and no compression of the portal bifurcation was observed. In November 2013, the tumor had vacated segment 2 and part of segment 4 of the liver.

Latest results:

In February 2014 she underwent successful surgery to remove the cancer, as the decrease in tumor size and no longer compressing blood vessels, made the surgery possible. At this moment she is stable and it was decided to continue one more year of treatment with Escozul™, to try to prevent recurrence of the disease.

If you would like more information about the case, please write to servicios@lifescozulcuba.com

Medical Documents

Initial Diagnosis:

Liver cancer (hepatocarcinoma) with metastasis to abdomen and alcoholic cirrhosis. He was evicted, untreated and with a prognosis of 1 month to live in September 2014.

Patient's condition before starting treatment:

• - Abdominal pain
• - Difficulty sleeping
• - Anxiety
• - Headaches.

Treatments received:

The patient started with us in early October 2014, being terminally ill. He was prescribed a high dose of Escozul™, considering the poor prognosis for life and indicating that we would work on the basis of achieving quality of life as the primary objective given the progression of the disease.

Escozul™ has the property of selectively killing cancer cells without killing healthy cells. Depending on the type of cancer, its degree of progression and the patient's physical condition, these properties of Escozul™ can lead to: slowing the progression of the disease, controlling the disease (no further progression), decreasing the size of tumor lesions, or eliminating tumor lesions. Any of these results lead to extending the patient's lifespan.

Current results:

By January 2015, when the first re-evaluation of the case was done, the patient had not only exceeded his life expectancy but his symptoms improved and the doctors gave him 3 to 6 months to live.

Escozul™ was achieved with Escozul™:

• -Significantly extended the patient's life time and prognosis.
• -The patient's initial symptoms disappeared.
• -He only presents occasional lack of appetite and tiredness.

Summary:

THE result obtained in this patient is above the average results obtained in patients with a life prognosis of less than 3 months. The response to treatment has been higher than expected and demonstrates the potential of Escozul™ in certain types of cancer. And although we are far from achieving that the patient overcomes the disease, he feels and so do we that it can be achieved.

Medical Documents